Dayvigo vs Trazodone: Titration Speed and Tolerability Compared

The Central Evidence Gap: No Head-to-Head Trial

Dayvigo and trazodone have not been randomized against each other for insomnia. Dayvigo's efficacy comes from placebo- and active-comparator trials, including SUNRISE 1 in adults age 55 and older 1 and SUNRISE 2 in adults with insomnia 2. Trazodone evidence consists of smaller and more heterogeneous studies summarized in reviews and guidelines 3.

That means statements that one works “twice as fast,” causes a particular percentage less grogginess, or is categorically safer are not supported by a direct comparison. Titration also is not a fair like-for-like metric: Dayvigo has a two-strength FDA label, whereas trazodone has no labeled insomnia titration at all.

How Dayvigo Is Dosed

The current FDA prescribing information for Dayvigo recommends 5 mg no more than once per night, immediately before going to bed and with at least seven hours remaining before planned awakening. The dose may be increased to 10 mg based on clinical response and tolerability. Ten milligrams is the maximum recommended dose.

The label does not require a three-day, seven-day, or one-week escalation. A prescriber may reassess after enough experience to judge benefit and next-day effects. Taking Dayvigo with or soon after a meal may delay sleep onset.

Moderate hepatic impairment limits both the initial and maximum dose to 5 mg; severe hepatic impairment is not recommended. Strong or moderate CYP3A inhibitors should be avoided, and CYP3A inducers may reduce exposure. These instructions replace older claims that an interacting medicine merely “caps” Dayvigo at 5 mg.

How Trazodone Is Used for Insomnia

The current professional prescribing information for trazodone covers major depressive disorder. It does not establish a starting dose, target dose, maximum dose, or escalation interval for insomnia. Commonly reported low-dose practices should not be presented as a standardized, FDA-validated sleep protocol.

The 2017 American Academy of Sleep Medicine guideline suggests that clinicians not use trazodone for sleep-onset or sleep-maintenance insomnia in adults 4. This is a weak recommendation based on limited evidence, not a declaration that trazodone can never be used. Later reviews found possible sleep benefits but continued to identify small studies, heterogeneous populations, and adverse effects including daytime drowsiness 3,5.

When trazodone is considered, the reason matters. A person taking it for major depression is not equivalent to someone offered it solely as an off-label hypnotic, and stopping an antidepressant requires attention to the underlying condition.

Tolerability Compared Without False Precision

An observational association does not prove trazodone caused every fall. Insomnia severity, frailty, other medicines, and underlying illness can confound comparisons. It is nevertheless inappropriate to claim trazodone is risk-free at “sleep doses.”

What Driving Research Actually Shows

A controlled on-road study in healthy adult and older volunteers found no statistically significant or clinically meaningful average driving impairment about nine hours after lemborexant doses up to 10 mg 7. That result does not override the current FDA label, which states that driving ability was impaired in some participants taking 10 mg and warns that individual sensitivity varies.

There is no sound basis for translating Dayvigo into a specific blood-alcohol concentration, and no direct driving study proves it causes less impairment than trazodone in patients with insomnia. People should not drive or perform hazardous work until they know how a prescribed sleep medicine affects them.

Switching Between Dayvigo and Trazodone

No clinical trial establishes a universal same-night switch, washout period, cross-taper, or overlap. A safe plan depends on:

• the current trazodone dose and whether it treats depression as well as sleep;
• other serotonergic or CNS-depressant medicines;
• alcohol, opioids, benzodiazepines, and sedating antihistamines;
• fall history, orthostatic symptoms, arrhythmia risk, and sleep apnea;
• liver function and CYP3A interactions;
• whether Dayvigo caused complex sleep behavior or severe next-day impairment; and
• the reason the current medicine is being stopped.

The Dayvigo label warns that combining it with other CNS depressants increases CNS depression and daytime impairment, and it says using Dayvigo with other insomnia drugs is not recommended. The trazodone label also warns about cognitive and motor impairment and enhanced effects with other CNS depressants. Therefore, an online instruction to overlap the two for one or two nights is not evidence based.

Trazodone should not be described as always safe to stop abruptly at a particular “sleep dose.” Its current label advises gradual reduction whenever possible. Conversely, the need for a Dayvigo taper is not established as a universal requirement. The prescriber should individualize the transition rather than apply a fabricated calendar.

Which Factors May Favor One Option?

Dayvigo may be considered when an FDA-approved insomnia medicine with randomized trial evidence is preferred and the person has no narcolepsy or problematic interaction. Its labeled two-dose range makes dose selection simpler, but Schedule IV status, access, and next-day impairment can matter.

Trazodone may still be considered in selected patients, particularly when depression treatment is also relevant, but insomnia use is off-label and the evidence is less certain. Orthostatic hypotension, falls, cardiac risk, hyponatremia, serotonergic interactions, and discontinuation planning deserve explicit review.

Cognitive behavioral therapy for insomnia remains the recommended initial treatment for chronic insomnia in most adults; medication comparisons should not obscure evaluation of sleep schedule, apnea, restless legs, substance use, mood disorders, and other drivers of poor sleep 8.